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1. Introduction 
Conjugation with glutathione is a major detoxica- 
tion pathway for many alkene and arene oxides, as 
well as a variety of other electrophilic compounds 
[l-3]. The significance of this pathway for epoxide 
metabolism is accentuated by the findings that the 
competing epoxide hydrase pathway is involved in 
the enzymatic synthesis of what may be the ultimate 
carcinogen from benzo[a]pyrene [4] and other 
polycyclic aromatic hydrocarbons, and that there is 
relatively much higher in vitro activity of glutathione 
S-transferases than epoxide hydrase in several mam- 
malian tissues [5]. 
A variety of aprotic solvents have been employed 
as vehicles for the lipophilic substrates of the gluta- 
thione S-transferases, including acetone [6], acetoni- 
trile [1,2,5,7-l 11, dimethyl sulfoxide [2,6,12-141, 
ethanol [ 12-201, methanol [ 1,2 l] and tetrahydro- 
furan [ 1,2,10,11]. However, little attention has been 
paid to the effects of these solvents on the enzymes 
studied, even in highly sophisticated kinetic analyses. 
We have shown that commonly used solvents have 
profound, substrate-dependent effects on various 
monooxygenase reactions in vitro [22]. 
We demonstrate here the inhibitory effect of 12 
aprotic solvents on styrene oxide conjugation with 
glutathione catalyzed by the microsomal supernatant 
fraction of rat liver. Inhibition is most pronounced at 
low substrate concentrations, but statistically signif- 
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icant even at high substrate concentrations. The 
enzymatic conjugation of 1,2-dichloro+ritrobenzene 
with glutathione is inhibited by ethanol, methanol, 
acetonitrile and tetrahydrothiophene dioxide, and 
that ofbenzo[a]pyrene4,5oxide by tetrahydrofuran, 
dioxane and tetrahydrothiophene dioxide. 
2. Experimental 
The soluble fraction (176 000 X g supernatant) 
was prepared from livers of adult male specific 
pathogen-free Sprague-Dawley rats as in [.5] and was 
used as the enzyme source after dilution to l-3 mg 
protein/ml. Protein content of these preparations 
was determined by the Lowry method [23] and 
bovine serum albumin was used as the reference 
standard. The rate of enzyme-catalyzed conjugation 
of styrene oxide and benzo[a]pyrene 4,5-oxide was 
determined essentially as in [5]. [14C]Styrene oxide 
(final cont. 50 PM or 1 mM as indicated) was added 
in 1~1 acetonitrile and [3H]benzo[a]pyrene 4,5-oxide 
(4,5-BPO) in 1 ~1 dimethyl sulfoxide in 0.9 ml total 
incubation vol. To correct for nonenzymic conjuga- 
tion, a control was run without tissue; the effect of 
tissue on carryover of radioactivity was determined 
by running nonincubated controls with and without 
added tissue. The incubation was stopped by adding 
2.4 ml ethyl acetate followed by immediate thorough 
mixing. The formed dihydrodiols and phenols were 
removed along with the unreacted oxides by 3 extrac- 
tions with ethyl acetate. The radioactivity in the 
remaining aqueous phase, representing solely the con- 
jugate [2], was counted. The incubations were carried 
out in triplicate. Conjugation of 1,2-dichloro-4- 
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nitrobenzene was followed at 350 nm in a Beckman 3. Results and discussion 
Acta III spectrophotometer using a nonenzymic rem 
tion mixture as the reference [24]+ The total reaction The main emphasis of this study was to investigate 
volume was 3 ml and the final concentration of the the effects of various organic solvents commonly used 
substrate was 50 frM added in 10 .LL~ dimethyl sulfoxide. as vehicles for substrates in assays for ~u~athione 
With ail 3 substrates, the incubation mixture was S-transferase activity. Therefore, the solvents were 
buffered with 0.133 M Hepes-NaOH buffer (pW 7.85) compared on a v/v basis and not on a molar concentra- 
and the concentration of glutathione was 3.5 mM. tion basis. The results are shown in table 1. 
The initial linear reaction velocity was determined. All organic solvents studied effectively inhibited 
Table 1 
Effect of organic solvents on the gIutathiane S-rransferase activity of rat tiver soluble fraction uiith 
styrene oxide, benzo[afpyrcne 4S-oxide or ~,2-dicllioro~-njtrobenzene 
____-. -.- __-. - 
Solvent Concentration Glutathione S-transferase activity” 
% (v/v) mol/l ” - ~_____ -__. I- 
S tyrene oxide Benzo[a]pyrenc 1,2-DichIoro+ 
4,5-oxide nitrobenzene 
Acetone 
Acetonitrile 
l,~-Di~~~~~~~~~~a~e 
Dimethylformamide 
Dimethyl sulfoxide 
Diaxane 
I ,3-Dioxolane 
Ethanol 
Methanol 
Bis-(2;Methoxyefhyt)- 
ether 
Tetrahydrofuran 
Tetrahydrothiophene 
1 ,l+dioxide 
3.3 0.45 47.2 + 3.9b 
0.56 O.O75 85.7 f 6.1 
3.3 0.63 79.0 + 5.2c 
3.3 0.63 48.8 i 4.5 
0.56 0.11 83.8 i 3.4 
0.11 0.021 95.4 + 5.7 
3.3 0.32 51.2 i 11.4 
0.56 0.054 73.0 t 9.0 
3.3 0.43 61.4 + 4.7 
0.56 0.072 93.4 f 3.6 
3.3 0.47 74.5 + 4.4 
0.56 0.078 95.9 * 5.5 
3.3 0.39 45.5 * 8.6 
0.56 0.065 77.0 A 13.1 
3.3 0.47 47.1 f 8.7 
0.56 0.079 81.0~ 6.8 
3.3 0.57 43.0 + 5.7 
0.56 o.a95 83.6 ? 3.8 
3.3 0.82 57.9 f 3.7 
0.56 0.14 88.5 + 2.5 
3.3 0.23 60.1 + 10.6 
0.56 0.039 82.8 i 7.1 
3.3 0+4 1 25.7 f. 9.6 
0.33 0.041 75.9 * 6.5 
0.11 0.014 81.6 + 4.4 
3.3 0.35 38.7 * 4.8 
89.4 t 5.5 80.1 f 4.5 
92.6 + 3.0 59.2 + 1.4 
80.4 5 6.8 
91.7 Yk 6.2 
85.9 -L 5.5 
59.0 A 6.9 
87.7 + 5.4 
83.9 * 4.9 
85.1 -t 4.7 
78.6 i 3.1 
60.7 A 14.0 
81.3 s 1.2 
93.5 + 3.3 
44.0 + 6.2 
103 -t 0.9 
84.6 + 2.5 
85.8 + 3.9 
47.3 +_ 0.6 
90.1 * 10.4 
62.9 f 0.1 
60.6 -r 1.9 
II2 t 15.1 
93.5 i 7.2 
60.4 * 5.2 
a Expressed as % control. activity (47.X t 13.4,55.4 + 11.2, and 9.72 s 0.79 ~~n~ol~~lin/rn~ proteinb 
for styrene oxide, benzo[a]pyrene 4,5-oxide and 1,2-dichloro&nitrobenzene, respectively). The 
solvents and solvent concentrations used in the control incubation mixtures were 0.11% (v/v) 
acetonitrilc for styrene oxide, 0.11% (v/v) dimethyl sulfoxide for benzo[a]pyrcne 4,5_oxide, and 
0.33% (V/Y) dimethyl sulfoxide for 1,2-dichlorobenzene. Finirl@tathione concentration was 3.5 mM 
for each substrate. The substrate concentrations were 50 #M, 10 PM and 50 &M for styrene oxide, 
benzo[a]pyrene 4.5-oxide, and f.2dfi~~~~oro-4-nitrobenzene, respzcti~ely 
b Mean + SD (n = 4 rats) 
c Styrene oxide was 1 mM 
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the enzymatic conjugation of styrene oxide with 
~utathione. However, when 1 mM styrene oxide was 
employed as the substrate, the i~ibition was con- 
siderably less pronounced although it was still 
statistically significant. Acetonitrile (2.6% v/v) was 
reported [9] not to affect styrene oxide conjugation 
by Wistar rat supernatant function when 1 mM sub- 
strate was used. The substrate in this study was added 
in 1 gl (O.l%, v/v) acetonitrile. Doubling this con- 
centration of solvent did not significantly alter the 
observed enzyme activity. Thus, it seems possible to 
use 0.1% acetonitrile as the vehicle for styrene oxide 
even at low substrate concentrations (50 PM), which 
are required in kinetic studies. Of the solvents tested, 
the most effective inhibitor of styrene oxide conjuga- 
tion was tetrahydrofuran. Concentrations as low as 
0.11% still caused a statistically significant decrease 
of enzyme activity (-20%). Distillation of tetrahydro- 
furan (to remove the butylated hydroxytoluene used 
as preservative) immediately prior to use did not 
affect enzyme inhibition. 
Benzo[a]pyrene 4,5-oxide hasvery limited solubility 
in water [lo]. Therefore, it was studied only at 
10 PM. The solvents investigated inhibited its con- 
jugation much less than that of either styrene oxide 
or 1,2-dichloro~-rlitrobenzene. Tetr~ydrofuran, a 
good solvent for the storage of arene oxides at 
reduced temperatures [25,26], was a potent inhibitor, 
as were dioxane and tetrahydrothiophene dioxide. 
Dimethylformamide and acetone, even at high con- 
centrations, did not cause any significant enzyme 
inhibition with this arene oxide substrate. The con- 
spicuously higher affinity of polycyclic arene oxides 
for glutathione S-transferases [2,10,1 l] may explain 
the relative lack of solvent effects on the enzymic 
conjugation of benzo[a]pyrene 4,5-oxide. 
1,2-Dichloro~-nitrobenzene is widely used as a 
substrate for ~uta~ione S-transferase activity. The 
enzymatic conjugation of this substrate with gluta- 
thione was intermediate between that of styrene oxide 
and benzo[a]pyrene 4,5oxide with respect to solvent 
sensitivity; of the 12 solvents tested, 5 were effective 
inhibitors. 
Conspicuous differences exist among the different 
substrates in their sensitivity toward different solvents: 
acetonitrile is a potent inhibitor of styrene oxide and 
1,2-dichloro4-nitrobenzene conjugation, but does 
not affect conjugation of benzo[a]pyrene 45oxide. 
Tetrahydrofuran is the most potent inhibitor of arene 
oxide conjugations but has no effect on 1,2-dichloro- 
4-nitrobenzene conjugation. Methanol and ethanol 
are among the most potent inhibitors of 1,2-dichloro- 
4nitrobenzene conjugation but have no marked 
effect on either of the other two substrates. The 
multiplicity of glutathione S-transferases in rat liver 
supernatant fraction [ 15,161, with overlapping 
specificities and wide variations in substrate affinities 
[10,11,15,16],may account for thepatternofsolvent 
inhibition of different substrates demonstrated here. 
With any substrate and enzyme source combination, 
it seems advisable to first check the effect of the 
solvents to be used on the conjugation rate, particu- 
larly if kinetic studies are anticipated. 
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